Clinical Trials Sponsored by Bharath Charitable Cancer Hospital and Institute

Total 2349 results

Tianjin Medical University Cancer Institute and...

Recruiting

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma

Pancreas Cancer | Predictive Cancer Model

China
Jinming Yu

Recruiting

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

PDAC - Pancreatic Ductal Adenocarcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

HER-2 Positive Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
Pingping Song

Not yet recruiting

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer(NSCLC)

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Gastric Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Early Detection of Pancreatic Cancer

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Chemotherapy

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

Unresectable | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China
Jinming Yu

Recruiting

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Non-small Cell Lung Cancer (NSCLC)

China
Tianjin Medical University Cancer Institute and...

Recruiting

Granisetron Transdermal Patch System for Prevention of CINV by CapeOX

Chemotherapy-induced Nausea and Vomiting

China
Tianjin Medical University Cancer Institute and...

Recruiting

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer | Bevacizumab | Tyrosine Kinase Inhibitor

China
Tianjin Medical University Cancer Institute and...

Recruiting

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

First-line Treatment | Advanced Gastric Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

MSI-H Advanced Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Colon Cancer | Immunotherapy | MSI-H | Adjuvant Therapy

China
Zhiyong Yu

Not yet recruiting

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Locally Advanced Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (KEYSTONE-003)

Pembrolizumab | Neoadjuvant Chemotherapy | Adenocarcinoma of Esophagogastric Junction

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction

Gastric Cancer | Peristaltic Direction | Roux-en-Y Gastrointestinal Anastomosis

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Lung Neoplasms | Lymph Node Excision

China
Tianjin Medical University Cancer Institute and...

Recruiting

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Breast Cancer | Fulvestrant | Palbociclib

China
Tianjin Medical University Cancer Institute and...

Recruiting

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection (AdBTC-1)

Cholangiocarcinoma | Gall Bladder Carcinoma

China
Tianjin Medical University Cancer Institute and...

Completed

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Active, not recruiting

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer Stage IV

China
Tianjin Medical University Cancer Institute and...

Completed

To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy

Enteral Nutrition | Esophageal Squamous Cell Carcinoma | Chemoradiotherapy

China
Tianjin Medical University Cancer Institute and...

Completed

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Carcinoma, Pancreatic Ductal

China
Tianjin Medical University Cancer Institute and...

Enrolling by invitation

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Peripheral T-cell Lymphoma Targeted Therapy

China
Tianjin Medical University Cancer Institute and...

Unknown

Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Squamous Cell Carcinoma of Head and Neck

China
Tianjin Medical University Cancer Institute and...

Unknown

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Triple-negative Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer

Gastric Cancer | Lymph Node Metastases | Exanimation

China
Tianjin Medical University Cancer Institute and...

Unknown

Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis

Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer

IIIB/IIIC/IV Lung Cancer

China
Rongjie Tao

Completed

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Efficacy and Safety

China
Zhiyong Yu

Unknown

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Breast Cancer | Chemotherapy Effect | Disease-free Survival

Clinical Trials Sponsored by Bharath Charitable Cancer Hospital and Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations